Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Guilhot

Showing results (121-130 of 154) with videos related to

Pageof 16
Sort By:
Leukemia|December 13, 2005
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantationF Millot, J Guilhot, B Nelken, et al.
British Journal of Haematology|October 16, 1999
Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de MoelleN Dhedin, S Giraudier, P Gaulard, et al.
Blood|September 9, 1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyR T Silver, S H Woolf, R Hehlmann, et al.
Bone Marrow Transplantation|November 5, 2003
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)F Millot, H Esperou, P Bordigoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patientsP Colonna, J P Jais, B Desablens, et al.
Leukemia|February 13, 2002
Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemiaH A Drabkin, C Parsy, K Ferguson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stagesJ M Andrieu, J P Jais, P Colonna, et al.
Blood Cancer Journal|September 20, 2014
Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusionA Maurizot, J-P Beressi, B Manéglier, et al.
Leukemia|March 31, 2012
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemiaD Rea, G Etienne, F Nicolini, et al.
Leukemia|June 4, 2011
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaC Roche-Lestienne, A Marceau, E Labis, et al.
Pageof 16

Showing results (121-130 of 154) with videos related to

Sort By:
Pageof 16
Leukemia|December 13, 2005
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantationF Millot, J Guilhot, B Nelken, et al.
British Journal of Haematology|October 16, 1999
Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Sociét Française de Greffe de MoelleN Dhedin, S Giraudier, P Gaulard, et al.
Blood|September 9, 1999
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of HematologyR T Silver, S H Woolf, R Hehlmann, et al.
Bone Marrow Transplantation|November 5, 2003
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)F Millot, H Esperou, P Bordigoni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patientsP Colonna, J P Jais, B Desablens, et al.
Leukemia|February 13, 2002
Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemiaH A Drabkin, C Parsy, K Ferguson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 1998
Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stagesJ M Andrieu, J P Jais, P Colonna, et al.
Blood Cancer Journal|September 20, 2014
Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusionA Maurizot, J-P Beressi, B Manéglier, et al.
Leukemia|March 31, 2012
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemiaD Rea, G Etienne, F Nicolini, et al.
Leukemia|June 4, 2011
Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemiaC Roche-Lestienne, A Marceau, E Labis, et al.
Pageof 16